Medical use of cannabis for glaucoma

      The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects, and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser, and surgical modalities for the treatment of glaucoma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zias J.
        • Stark H.
        • Sellgman J.
        • et al.
        Early medical use of cannabis.
        Nature. 1993; 363: 215
        • Lieberman M.F.
        “Recredicinal” marijuana.
        Am J Ophthalmol. 2017; 117: xv-xviii
        • Gaoni Y.
        • Mechoulam R.
        Isolation, structure and partial synthesis of the active constituent of hashish.
        J Am Chem Soc. 1964; 86: 1646-1647
        • Hepler R.S.
        • Frank I.R.
        Marihuana smoking and intraocular pressure.
        JAMA. 1971; 217: 1392
        • Merritt J.C.
        • Crawford W.J.
        • Alexander P.C.
        • Anduze A.L.
        • Gelbart S.S.
        Effect of marihuana on intraocular and blood pressure in glaucoma.
        Ophthalmology. 1980; 87: 222-228
        • Merritt J.C.
        • McKinnon S.
        • Armstrong J.R.
        • Hatem G.
        • Reid L.A.
        Oral delta 9‐tetrahydrocannabinol in heterogeneous glaucomas.
        Ann Ophthalmol. 1980; 12: 947-950
        • Purnell W.D.
        • Gregg J.M.
        Delta(9)‐tetrahydrocannabinol, euphoria and intraocular pressure in man.
        Ann Ophthalmol. 1975; 7: 921-923
        • Tomida I.
        • Azuara‐Blanco A.
        • House H.
        • Fling M.
        • Pertwee R.G.
        • Robson P.J.
        Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.
        J Glaucoma. 2006; 15: 349-353
        • Merritt J.C.
        • Olsen J.L.
        • Armstrong J.R.
        • McKinnon S.M.
        Topical delta 9‐tetrahydrocannabinol in hypertensive glaucomas.
        J Pharm Pharmacol. 1981; 33: 40-41
        • Green K.
        • Roth M.
        Ocular effects of topical administration of delta 9‐tetrahydrocannabinol in man.
        Arch Ophthalmol. 1982; 100: 265-267
        • Jay W.M.
        • Green K.
        Multiple‐drop study of topically applied 1% delta 9‐tetrahydrocannabinol in human eyes.
        Arch Ophthalmol. 1983; 101: 591-593
        • Green K.
        • Podos S.M.
        Antagonism of arachidonic acid‐induced ocular effects by D1‐tetrahydrocannabinol.
        Invest Ophthalmol. 1974; 13: 422-429
        • Porcella A.
        • Casellas P.
        • Gessa G.L.
        • Pani L.
        Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.
        Brain Res Mol Brain Res. 1998; 58: 240-245
        • Zhan G.L.
        • Camras C.B.
        • Palmber P.F.
        • Toris C.B.
        Effects of marijuana on aqueous humor dynamics in a glaucoma patient.
        J Glaucoma. 2005; 14: 175-177
        • Brown B.
        • Adams A.J.
        • Haegerstrom‐Portnoy G.
        • Jones R.T.
        • Flom M.C.
        Pupil size after use of marijuana and alcohol.
        Am J Ophthalmol. 1977; 83: 350-354
        • Hashibe M.
        • Ford D.E.
        • Zhang Z.F.
        Marijuana smoking and head and neck cancer.
        J Clin Pharmacol. 2002; 42: 103-107
        • Flom M.C.
        • Adams A.J.
        • Jones R.T.
        Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon.
        Invest Ophthalmol. 1975; 14: 52-55
        • Salomonsen-Sautel S.
        • Min S.J.
        • Sakai J.T.
        • Thurstone C.
        • Hopfer C.
        Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado.
        Drug Alcohol Depend. 2014; 140: 137-144
        • Choi N.G.
        • Marti C.N.
        • DiNitto D.M.
        • Choi B.Y.
        Older adults’ marijuana use, injuries, and emergency department visits.
        Am J Dug Alcohol Abuse. 2018; 44: 215-223
        • Campbell C.I.
        • Bahorik A.L.
        • Kline-Simon A.H.
        • Satre D.D.
        The role of marijuana use disorder in predicting emergency department and patient encounters: a retrospective cohort study.
        Drug Alcohol Depend. 2017; 178: 170-175